Author: sHq_LoGiNz

• Eligible Medicare patients living with obesity will have access to Wegovy^® (semaglutide) injection and pill for a $50 monthly copay
• Wegovy^® offers adults living with obesity significant weight loss, along with diet and exercise, and is FDA-approved to lower the risk of major CV events such as death, heart attack, or stroke in adults living with obesity with known heart disease, a claim only Wegovy^® can make
• Novo Nordisk’s participation in the Medicare GLP-1 Bridge expands patient access to authentic, FDA-approved Wegovy^®

PLAINSBORO, N.J., May 7, 2026 /PRNewswire/ — The Medicare GLP-1 Bridge will provide eligible Medicare beneficiaries living with obesity access to Wegovy^® (semaglutide) injection and tablets for a $50 monthly copay^†, beginning July 1, 2026, per yesterday’s announcement from the Centers for Medicare & Medicaid Services (CMS). The program represents a meaningful milestone in making FDA-approved Wegovy^® accessible for millions of America’s Medicare patients living with obesity, who can now work with their healthcare professional to start and stay on proven, FDA-approved treatment.

“Obesity is a serious, common chronic disease facing older Americans, and Wegovy^® is the only weight management medicine proven to reduce the risk of heart attack, stroke, or cardiovascular death in patients who also have known heart disease. That distinction matters for seniors age 65 and older, who have a high burden of both conditions,” said Jamey Millar, executive vice president, US Operations of Novo Nordisk. “We welcome the Medicare GLP-1 Bridge as an important step in getting Wegovy^® to more patients and will continue to work with CMS, healthcare professionals, pharmacists, and patient advocates to support implementation and help eligible seniors access the care they need and deserve.”

The Medicare GLP-1 Bridge provides eligible patients access to Wegovy^® for weight management. The Medicare GLP-1 Bridge will be available nationwide across all states and territories, providing eligible patients access to all doses and formulations of Wegovy^® injection and Wegovy^® pill, and will run through the end of 2027. It is important to note that Wegovy^® will be available for eligible Medicare beneficiaries for the other FDA-approved indications through their normal Part D benefits, including to reduce the risk of major adverse cardiovascular events in adults with established CV disease with either obesity or overweight.

Novo Nordisk is actively working with CMS, healthcare professionals, pharmacists, and patient advocacy organizations to streamline implementation, raise awareness among eligible beneficiaries, and help ensure patients can access the medicines they need. Additional program details are available at CMS.gov.

Expanding affordable access to medicines is a priority for Novo Nordisk, and the Medicare GLP-1 Bridge builds on a sustained effort to ensure patients can access authentic, FDA-approved Wegovy^®. Patients seeking information on affordability options, with or without insurance, are encouraged to visit NovoCare.com.

^†Terms apply. For eligible Medicare patients prescribed Wegovy^® for a covered FDA-approved indication. Eligibility criteria will be determined by CMS. This information is not a guarantee of coverage. Month defined as 1 box of 4 pens of Wegovy^® and 1 bottle of 30 tablets of Wegovy^®.

About obesity
Obesity is a serious, chronic, progressive, and complex disease that requires long-term management.^1-3 One key misunderstanding is that this is a disease of just lack of willpower, when in fact there is underlying biology that may impede people living with obesity from losing weight and keeping it off.^1,3 Obesity is influenced by a variety of factors, including genetics, social determinants of health, and the environment.^4,5

About Novo Nordisk
Novo Nordisk is a leading global healthcare company that’s been making innovative medicines to help people with diabetes lead longer, healthier lives for more than 100 years. This heritage has given us experience and capabilities that also enable us to drive change to help people defeat other serious chronic diseases such as obesity, rare blood and endocrine disorders. We remain steadfast in our conviction that the formula for lasting success is to stay focused, think long-term, and do business in a financially, socially, and environmentally responsible way. With a US presence spanning 40 years, Novo Nordisk US is headquartered in New Jersey and employs approximately 10,000 people throughout the country across more than 10 manufacturing, R&D and corporate locations in seven states plus Washington DC. For more information, visit novonordisk-us.com, Facebook, Instagram, and X.

What is Wegovy^®?
Wegovy^® (semaglutide) injection is a prescription medicine used with a reduced-calorie diet and increased physical activity to:

• reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and with either obesity or overweight.
• help adults and children aged 12 years and older with obesity, or some adults with excess weight (overweight) who also have weight-related medical problems to lose weight and keep the weight off.

Wegovy^® (semaglutide) tablets are a prescription medicine used with a reduced-calorie diet and increased physical activity to:

• reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and with either obesity or overweight.
• help adults with obesity, or some adults with excess weight (overweight) who also have weight related medical problems to lose weight and keep the weight off.

Wegovy^® contains semaglutide and should not be used with other semaglutide-containing products or other GLP-1 receptor agonist medicines.

It is not known if Wegovy^® injection is safe and effective:

• to reduce the risk of major cardiovascular events (death, heart attack, or stroke) in people under 18 years
• to help children under 12 years of age lose weight and keep the weight off.

It is not known if Wegovy^® tablets are safe and effective for use in people under 18 years of age.

Important Safety Information

What is the most important information I should know about Wegovy^®?

Wegovy^® may cause serious side effects, including:

• Possible thyroid tumors, including cancer. Tell your healthcare provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath. These may be symptoms of thyroid cancer. In studies with rodents, Wegovy^® and other medicines that work like Wegovy^® caused thyroid tumors, including thyroid cancer. It is not known if Wegovy^® will cause thyroid tumors or a type of thyroid cancer called medullary thyroid carcinoma (MTC) in people
• Do not use Wegovy^® if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)

Do not use Wegovy^® if:

• you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• you have had a serious allergic reaction to semaglutide or any of the ingredients in Wegovy^® injection or Wegovy^® tablets. See symptoms of serious allergic reaction in “What are the possible side effects of Wegovy^®?”

Before using Wegovy^®, tell your healthcare provider if you have any other medical conditions, including if you:

• have or have had problems with your pancreas or kidneys
• have type 2 diabetes and a history of diabetic retinopathy
• are scheduled to have surgery or other procedures that use anesthesia or deep sleepiness (deep sedation)
• are pregnant or plan to become pregnant. Wegovy^® may harm your unborn baby. You should stop using Wegovy^® 2 months before you plan to become pregnant
• are breastfeeding or plan to breastfeed. Breastfeeding is not recommended during treatment with Wegovy^® tablets. It is not known if Wegovy^® when received through an injection passes into your breast milk

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Wegovy^® may affect the way some medicines work and some medicines may affect the way Wegovy^® works. Tell your healthcare provider if you are taking other medicines to treat diabetes, including sulfonylureas or insulin. Wegovy^® slows stomach emptying and can affect medicines that need to pass through the stomach quickly.

What are the possible side effects of Wegovy^®?
Wegovy^® may cause serious side effects, including:

• inflammation of your pancreas (pancreatitis). Stop using Wegovy® and call your healthcare provider right away if you have severe pain in your stomach area (abdomen) that will not go away, with or without nausea or vomiting. Sometimes you may feel the pain from your abdomen to your back
• gallbladder problems. Wegovy^® may cause gallbladder problems, including gallstones. Some gallstones may need surgery. Call your healthcare provider if you have symptoms, such as pain in your upper stomach (abdomen), fever, yellowing of the skin or eyes (jaundice), or clay-colored stools
• increased risk of low blood sugar (hypoglycemia), especially those who also take medicines for diabetes such as insulin or sulfonylureas. This can be a serious side effect. Talk to your healthcare provider about how to recognize and treat low blood sugar and check your blood sugar before you start and while you take Wegovy®. Signs and symptoms of low blood sugar may include dizziness or light-headedness, blurred vision, anxiety, irritability or mood changes, sweating, slurred speech, hunger, confusion or drowsiness, shakiness, weakness, headache, fast heartbeat, or feeling jittery
• dehydration leading to kidney problems. Diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems. It is important for you to drink fluids to help reduce your chance of dehydration. Tell your healthcare provider right away if you have nausea, vomiting, or diarrhea that does not go away
• severe stomach problems. Stomach problems, sometimes severe, have been reported in people who use Wegovy^®. Tell your healthcare provider if you have stomach problems that are severe or will not go away
• serious allergic reactions. Stop using Wegovy^® and get medical help right away if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue, or throat; problems breathing or swallowing; severe rash or itching; fainting or feeling dizzy; or very rapid heartbeat
• change in vision in people with type 2 diabetes. Tell your healthcare provider if you have changes in vision during treatment with Wegovy^®
• increased heart rate. Wegovy^® can increase your heart rate while you are at rest. Tell your healthcare provider if you feel your heart racing or pounding in your chest and it lasts for several minutes
• food or liquid getting into the lungs during surgery or other procedures that use anesthesia or deep sleepiness (deep sedation). Wegovy^® may increase the chance of food getting into your lungs during surgery or other procedures. Tell all your healthcare providers that you are taking Wegovy^® before you are scheduled to have surgery or other procedures

The most common side effects of Wegovy^® may include: nausea, diarrhea, vomiting, constipation, stomach (abdomen) pain, changes in skin sensations, headache, tiredness (fatigue), upset stomach, dizziness, feeling bloated, belching, low blood sugar in people with type 2 diabetes, gas, stomach flu, heartburn, and hair loss.

Please click here for Prescribing Information including Boxed Warning and Medication Guide for Wegovy^®.

Contacts for further information

References:

1. Kaplan LM, Golden A, Jinnett K, et al. Perceptions of barriers to effective obesity care: results from the national action study. Obesity. 2018;26(1):61–69.
2. Bray GA, Kim KK, Wilding JPH; World Obesity Federation. Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. Obes Rev. 2017;18(7):715–723.
3. Garvey WT, Mechanick JI, Brett EM, et al. American association of clinical endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22 (Suppl 3):1–203.
4. Wharton S, Lingvay I, Bogdanski P, et al. Oral semaglutide 25 mg in adults with overweight or obesity. N Engl J Med. 2025; 393:1077-1087. DOI: 10.1056/NEJMoa2500969.
5. Centers for Disease Control and Prevention. Risk Factors for Obesity. Last accessed: December 2025. Available at: https://www.cdc.gov/obesity/risk-factors/risk-factors.html

View original content to download multimedia:https://www.prnewswire.com/news-releases/wegovy-access-expanded-for-medicare-beneficiaries-living-with-obesity-through-the-medicare-glp-1-bridge-starting-july-1-2026-302764949.html

SOURCE Novo Nordisk

BOSTON, May 7, 2026 /PRNewswire/ — VOTF, a Catholic Lay Apostolate committed to promoting transparency in Church operations, has published its 2025 diocesan financial transparency report. Before being released publicly, the reports were sent to each diocesan bishop and to CFOs of each of the 176 geographical dioceses in the USCCB. The average overall 2025 transparency score dropped 6 points from 71% to 66%. In 2025, the number of dioceses posting current audited financial reports of their central operations decreased from 114 to 112 (64%). The all-time high for posting current audited reports was 116 dioceses in 2023. More details for the 2025 results may be found here.

The downward trend in reporting observed in 2025 is due primarily to dioceses failing to post the information in a timely fashion. Our hope is that dioceses will make progress toward more consistent financial reporting going forward. Despite lower scores the overall financial transparency picture is still positive, with many dioceses demonstrating dedication to transparency and accountability. Five dioceses scored 100%, while only six scored 20% or lower. The Archdiocese of Kansas City in Kansas and the Dioceses of Lexington KY, Nashville TN, Rochester NY and Youngstown OH received perfect transparency scores in 2025. The Archdiocese of New York once again received the lowest transparency score in the USCCB at 12%.

Four other New York dioceses are going through bankruptcy proceedings as a way of dealing with large claims of clerical child sexual abuse, but the Archdiocese has thus far avoided the financial disclosure that accompanies bankruptcy by selling land holdings in New York City to raise $300 million dollars for abuse settlements. New York received a score of 37% in 2021, 2022 and 2023 but dropped to 12% in 2024 as the financial problems facing the Archdiocese mounted. Sharing more financial information, not less, will help to regain needed trust and support from members of the Archdiocese. We are hopeful that New York will rebound from its position as the lowest scorer in the U.S. under new diocesan leadership and provide an exampleof financial transparency and accountability to the other members of the USCCB.

VOTF congratulates those dioceses that led the way in transparency and accountability in 2025 and those that made significant gains this year as well. We remain committed to working for transparency throughout the Church. Such transparency can enhance lay stewardship, promote generosity, and build trust in the leadership of the Catholic Church nationwide.

Voice of the Faithful News Release, April 27, 2026, Margaret Roylance, mroylance@votf.org, (781) 559-3360

Voice of the Faithful^®: Voice of the Faithful’s^® mission is to provide a prayerful voice, attentive to the Spirit, through which the Faithful can actively participate in the governance and guidance of the Catholic Church. VOTF’s goals are to support survivors of clergy sexual abuse, to support priests of integrity, and to shape structural change within the Catholic Church. More information is at www.votf.org.

View original content to download multimedia:https://www.prnewswire.com/news-releases/voice-of-the-faithful-votf-releases-results-of-the-2025-diocesan-financial-transparency-review-302765016.html

SOURCE Voice of the Faithful

KUNSHAN, China, May 7, 2026 /PRNewswire/ — Arctech, a world-leading solar tracking and smart energy solution provider, held a launch ceremony for its ArcTrack Mobile Solar-Tracking & Storage Microgrid Solution in Jakarta.

By innovatively integrating solar, storage, intelligence, and control into one system, ArcTrack delivers a reliable, efficient, and cost-effective energy solution for every off-grid and temporary power scenario ­- providing stable and safe power for all scenarios, enabling fast and efficient installation and O&M, and optimizing lifecycle cost-benefit while improving end-to-end carbon efficiency.

Specifically, it provides stable power in extreme conditions from -30°C to 60°C, while withstanding force‑10 winds, and can be installed by two people in just one day with plug‑and‑play operation, supporting up to six parallel units. The system optimizes lifecycle costs by delivering 20% lower transport, 50% less site prep, 40% higher asset utilization, and over 400% ROI, while reducing the levelized cost of electricity by up to 90%. Each unit can cut CO₂ emissions by 32.4 tons annually.

At the ceremony, Arctech Chairman Mr. Cai reaffirmed the company’s commitment to localizing manufacturing and services, while a strategic partnership with PT Pilar was announced to strengthen regional value chains.

Over the following three days at SolarTech Indonesia Exhibition, the spotlight remained on ArcTrack. Live demos of the mobile microgrid drew strong interest from engineers and EPC partners, highlighting its plug‑and‑play deployment and off‑grid economics.

Alongside ArcTrack, Arctech also showcased its SkyLine II tracker (adapting to 30° slopes) and SkyFlex large-span cable mounting system (15–60m spans), further demonstrating the company’s ability to address Indonesia’s hilly terrain and dispersed project sites.

The solutions demonstrated Arctech’s deepened commitment to Indonesia’s ambitious energy transition, addressing the country’s unique archipelagic terrain, grid gaps, and complex installation conditions. As the leading tracker provider in the Asia-Pacific region for consecutive years, Arctech is doubling down on its local team, technical support, and end-to-end service capabilities – with the same commitment extending across Southeast Asia.

Moving forward, Arctech will continue to drive customer-centric innovation, deepening its participation from project investment and business model creation to customized smart energy development. Together with local partners, the company is committed to building a resilient green grid across Indonesia and beyond.

Learn more about Arctech: https://en.arctechsolar.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/arctech-launched-arctrack-mobile-solar-tracking–storage-microgrid-solution-at-solartech-indonesia-2026-powering-indonesias-green-transition-302765432.html

SOURCE Arctech Solar

NINGDE, China, May 7, 2026 /PRNewswire/ — On April 29^th, Contemporary Amperex Intelligent Technology (Shanghai) Limited (CAIT), CATL’s skateboard chassis arm, has entered into a strategic partnership with Turkish automotive brand Togg to jointly develop chassis platform for its new B-segment vehicle family, marking the first overseas passenger vehicle project for the platform.

Under the agreement, CAIT will contribute its Bedrock Chassis technology and engineering expertise, while working closely with Togg to co-develop the platform for three models in Togg’s new B-segment vehicle family. Developed in line with Togg’s product strategy, user expectations and mobility ecosystem, the platform will support next-generation electric vehicles for the Turkish and European markets, with Togg playing a defining role in shaping the user experience, product requirements and digital architecture. The first model developed under the partnership is expected to enter mass production in 2027.

Battery-centric chassis architecture

The Bedrock Chassis is an integrated intelligent chassis built around a “battery-centric” architecture. It combines core chassis components including the battery, electric drive system, thermal management system and chassis domain controller into a single platform. This integration allows the chassis to manage both vehicle energy and motion control, effectively acting as a mobile energy carrier for the vehicle.

Robin Zeng, Chairman and CEO of CATL, said, “This collaboration represents another important milestone in the global expansion of the CATL Bedrock Chassis following its mass production rollout in the Chinese market. It will also serve as a benchmark project in the field of integrated intelligent chassis, strengthening our global partnerships, accelerating electrification and supporting the transition to low-carbon mobility in emerging new energy markets.”

Commenting on the partnership, Togg Chairman Fuat Tosyalı said: “We see mobility not merely as a product category, but as a holistic matter of technology and ecosystem. In this direction, we are taking the partnerships we establish beyond conventional supplier relationships and turning them into strategic partnerships that create shared value and build the future together. Rather than adopting a ready-made solution, we are becoming part of the entire development process, responding more effectively to user needs while also contributing to the development of this ecosystem in our country. In the period ahead, through such value-creating partnerships, we will further enrich the Togg ecosystem and the experience we offer our users by developing new solutions across different segments.”

Localised model for global markets

The Bedrock Chassis has been developed for global deployment through a “1+1+1” localisation model. This model combines one chassis technology platform with one industrial supply chain pathway and the localised operation of one domestic automotive brand. The aim is to allow electric vehicles to be designed and produced in ways that reflect the needs of local markets while using a common technological foundation.

The partnership with Togg is expected to apply this approach in Türkiye, supporting the development of vehicles tailored to regional consumer preferences while strengthening the local electric vehicle ecosystem.

Expanding international partnerships

In 2024, the Bedrock Chassis achieved mass production in the Chinese market, marking the world’s first deployment of an integrated intelligent chassis offered as a standalone product to passenger vehicle brands.

CAIT is continuing to expand cooperation around the Bedrock Chassis in several regions, including Europe and Southeast Asia. The platform is designed to help emerging automotive markets build competitive electric vehicle industries more efficiently, while supporting the global shift towards low-emission mobility.

View original content to download multimedia:https://www.prnewswire.com/news-releases/catl-subsidiary-cait-partners-up-with-togg-on-bedrock-chassis-302765410.html

SOURCE Contemporary Amperex Intelligent Technology (Shanghai) Limited (CAIT)

SHANGHAI, May 7, 2026 /PRNewswire/ — Pylontech (688063.SH), a leading global energy storage system provider, has been recognized as a BloombergNEF (BNEF) Tier 1 Energy Storage Manufacturer for Q2 2026, underscoring the company’s bankability, proven project execution capabilities, and established position in the global energy storage market.

The BNEF Tier 1 list is regarded as one of the industry’s most rigorous evaluation benchmarks for energy storage companies. The assessment considers factors including technological capabilities, product reliability, large-scale project execution track record, and financial credibility. Pylontech’s inclusion in the Tier 1 list reflects its growing global project portfolio and long-standing commitment to delivering reliable energy storage solutions across a wide range of applications and markets. Recent utility-scale projects delivered by Pylontech include the Ningxia Yinchuan 200MW/400MWh Energy Storage Project and the Jiangsu Huadian Yizheng 120MW/240MWh Energy Storage Power Station in China.

“BNEF Tier 1 recognition reflects the market’s confidence in Pylontech’s technology, product quality, and long-term reliability,” said a spokesperson for Pylontech. “This recognition further reinforces Pylontech’s position as a trusted partner for utility-scale and commercial energy storage projects worldwide.”

With more than a decade of expertise in energy storage innovation, Pylontech has established a vertically integrated platform spanning battery cells, modules, battery management systems (BMS), and system integration. The company continues to expand its global presence while supporting the transition toward a cleaner, more resilient, and sustainable energy future.

About Pylontech

Founded in 2009, Pylontech (688063.SH) is a dedicated energy storage system provider that went public on the STAR Market in 2020, becoming the first listed company in China focused on energy storage as its core business. With extensive expertise in electrochemistry, power electronics, and system integration, Pylontech has delivered reliable energy storage products and solutions to the global market, establishing itself as a leading player in the industry. Its products are widely used in various scenarios, including solutions for residential, C&I, grid-side storage, communication base station and data center energy storage, light-duty electric vehicles, battery-swapping and more. Website: https://en.pylontech.com.cn/?lan=en

View original content to download multimedia:https://www.prnewswire.com/news-releases/pylontech-recognized-as-bloombergnef-tier-1-energy-storage-manufacturer-302765354.html

SOURCE Pylontech

MONTREUX, Switzerland, May 7, 2026 /PRNewswire/ — From April 27-28, 2026, the World Business Council for Sustainable Development (WBCSD) Annual Meeting was held in Montreux, Switzerland. This premier global sustainability forum gathered nearly 600 participants from leading companies worldwide to discuss critical topics like the 2030 emissions reduction agenda and the circular economy.

Linglong Tire’s President, Zhou Lingkun, was invited to speak at the “China Sustainable Business Practice” session. He stated that in the context of global “dual carbon” goals, sustainable development has become a mandatory task for businesses. Linglong has integrated green and low-carbon principles into its core strategy, aiming to build a green ecosystem across the entire industrial chain. The company has set clear carbon neutrality targets: a 52.07% reduction by 2035 and achieving net-zero emissions by 2050.

During the meeting, Linglong Tire was officially presented with its WBCSD membership certificate. As the first tire manufacturer in mainland China to join the Global Platform for Sustainable Natural Rubber (GPSNR), Linglong supports FSC-certified natural rubber projects to support the livelihoods of rubber farmers, contribute to the preservation of forests and to protect the rights of workers, indigenous peoples and local communities. In the field of resource recycling, Linglong promotes the use of liquid waste rubber and pyrolysis carbon black to effectively use waste tires and ensure a closed resource cycle.

A key highlight was Linglong’s display of its newly developed tire composed of 85% sustainable materials. This tire utilizes over 60% bio-based renewable materials and about 25% recycled materials, placing it at the forefront of the Chinese tire industry and among global leaders. It employs innovative materials like rice husk ash silica and bio-based rubber to replace traditional petroleum-based ingredients, significantly reducing the product’s carbon footprint from the source. Importantly, it maintains top-tier performance, meeting the EU Tire Label’s highest ‘A’ grade standards in key areas like rolling resistance and wet braking.

President Zhou noted that the 85% sustainable material tire is just a new starting point. Linglong’s long-term goal is to achieve a 100% sustainable material tire by 2040. Joining WBCSD marks international recognition of its sustainability efforts, and the company plans to engage deeply in global discussions to collaborate on a greener future for mobility.

View original content to download multimedia:https://www.prnewswire.com/news-releases/linglong-tire-presents-sustainable-concept-tire-at-world-business-council-for-sustainable-development-302765315.html

SOURCE Shandong Linglong Tyre Co., Ltd.

STORA ENSO OYJ INTERIM REPORT 7 May 2026 at 8:30 EEST

HELSINKI, May 7, 2026 /PRNewswire/ — 

Q1/2026 (year-on-year)

• Sales remained stable at EUR 2,358 (2,362) million, as higher deliveries were offset by negative foreign exchange rate changes.
• Adjusted EBIT decreased by 9% to EUR 159 (175) million, as lower wood costs were offset by negative net foreign exchange rate and the ramp-up at the Oulu site. The adjusted EBIT margin decreased to 6.7% (7.4%).
• Operating result (IFRS) was EUR 85 (171) million, including items affecting comparability of EUR -56 (-11) million, and fair valuations and other non-operational items of EUR -18 (7) million.
• Earnings per share were EUR 0.04 (0.14) and earnings per share excl. fair valuations (FV) were EUR 0.05 (0.13).
• The fair value of the forest assets was EUR 8.5 (9.3) billion, equivalent to EUR 10.76 per share, reflecting the impact of the divestment of 12.4% of forest assets in Sweden in 2025.
• Cash flow from operations amounted to EUR 125 (192) million, reflecting higher restructuring-related site closure expenses and higher working capital.
• Cash flow after investing activities improved to EUR -22 (-47) million, mainly due to lower cash spending on fixed assets.
• The net debt to adjusted EBITDA (LTM) ratio improved to 3.1 (3.2).

Key highlights

• Stora Enso continues the preparations for the separation of its Swedish forest assets business into a new publicly-listed company, expected to be completed during the first half of 2027.
• Stora Enso’s strategic review of its Central European sawmills and building solutions operations is ongoing.
• The ramp-up of the consumer board line at the Oulu site in Finland continues, and the production volumes are gradually increasing. The line is expected to reach full capacity during 2027.
• Stora Enso’s segment reporting changed as of 1 January 2026, and the Group has restated the comparative figures for its segment reporting for 2025.
• Stora Enso’s Annual General Meeting on 24 March 2026 decided to distribute a dividend of EUR 0.25 per share for the year 2025 in two instalments, paid on 8 April 2026 and 2 October 2026

Outlook Q2/2026

• Market conditions remain challenging, with low consumer confidence and heightened geopolitical volatility.
• Geopolitical tensions, particularly the conflict in the Middle East, are expected to increase costs in 2026, especially for logistics, chemicals, and energy. The Group is working on measures to manage these pressures, but uncertainty persists regarding cost and market development.
• The ramp-up of the new production line in Oulu continues. In Q2, we expect the negative impact on adjusted EBIT to continue at a similar level as in Q1/2026.
• Planned maintenance activity in the second quarter is expected to be broadly in line with the first quarter of 2026.
• The divestment of 175,000 hectares of forest assets in Sweden, completed in 2025, will result in a reduction of annual adjusted EBIT of approximately EUR 20 million, with an estimated quarterly effect of approximately EUR 5 million.
• The operating income from emission rights in 2025 was about EUR 72 million, distributed evenly throughout the year. For 2026, the income from the sale of emission rights is projected to decrease to EUR 10–20 million. This decline results from changes in the EU ETS (Emissions Trading Scheme) rules: several sites will lose their free CO₂ allowance allocations from 2026 onward, as their emissions are now more than 95% biogenic, demonstrating the success of long-term emission-reduction initiatives.

Key figures

Stora Enso’s President and CEO Hans Sohlström comments on the results:

The first quarter of 2026 developed largely as expected, with stable performance in a market that remains challenging. Demand in our main end markets stayed at relatively low levels, and pricing pressure persisted in some business segments, while prices firmed up and increased in others. While market conditions remain challenging, we continue to drive performance through our own actions across operations, costs, commercial excellence, and procurement. 

In the early part of the quarter, we saw a positive development in demand. However, towards the end of the quarter, geopolitical tensions escalated with the outbreak of the war in Iran. While the impact on the first quarter’s performance was limited, these developments have increased uncertainty and are expected to affect the operating environment going forward. The situation adds to volatility and raises the risk of higher cost levels, particularly related to energy, logistics and other variable costs such as chemicals, with effects becoming more visible in the second quarter. 

Operationally, the ramp-up of the new consumer board line at Oulu continued. We focused on improving the technical runnability of production. This, in addition to the weak market, impacted profitability during the quarter and is expected to continue into the second quarter. While the ramp-up continues to impact short-term profitability, we remain confident in bringing the line to full operational performance during 2027. 

Preparations for the separation of our Swedish forest assets business, now named Bergslagets Skogar (formerly ForestCo), continued to progress as planned. A dedicated management team is in place, and we are preparing for a Capital Markets Day on 3 November 2026, which will provide further detail on the business, its strategy and financial profile. 

This quarter marks the first time we report under our new reporting structure, which reflects how we manage the business and how value is created across the Group. A key to value creation is the P&L responsibility across 6 Business Areas and 23 Business Units. I am pleased to see that this decentralised P&L responsibility is already having a positive effect through our leaders focusing on continuous profit improvement. This provides a strong foundation for performance culture going forward.

Our strategic priorities remain unchanged: 

• Lead in customer value creation through innovation, quality and sustainability
• Grow faster than market with superior customer offering, leading technology and operational efficiency
• Expand margin through business focus, a positive performance culture and systematic value creation
• Generate cash with high conversion ratio and disciplined capital allocation

We continue to strengthen our competitiveness and ability to deliver consistent performance regardless of external market volatility. 

I would like to thank our employees for their strong contribution at the start of the year. Together, we are building a stronger, more focused, and more sustainable Stora Enso.

Webcast for analysts, investors, and media 
Stora Enso’s President and CEO Hans Sohlström and CFO Niclas Rosenlew will present the results in a webcast today starting at 11:00 am EEST (10:00 CEST, 9:00 BST, 4:00 EST). The live the webcast can be accessed using the following link: https://stora-enso-q1-earnings-presentation-2026.open-exchange.net/.

During the webcast presentation, analysts and investors will also have the possibility to ask questions. To participate in the teleconference, please choose the “Teleconference” option on the homepage of the webcast. Recording of the webcast will be available shortly after the event at the same address and at storaenso.com.

Media representatives who wish to ask questions after the publication of the report may contact Hanna Rutanen, SVP Communications at Stora Enso on +358 41 507 1361

Save the date: Bergslagets Skogar will organise a Capital Markets Day on 3 November 2026 in Stockholm.

This release is a summary of Stora Enso’s Interim Report January–March 2026. The complete report is attached to this release as a pdf file, and it is also available on the company website.

For further information, please contact:
Jutta Mikkola
SVP Investor Relations
tel. +358 50 544 6061

Hanna Rutanen
SVP Communications
Tel. +358 41 507 1361

Stora Enso is a global leader in renewable materials with a strong focus on packaging. Our purpose is to replace non-renewable materials with renewable solutions. Together with our customers, we design and deliver competitive, high-quality packaging materials and solutions, made from fresh and recycled fibers, accelerating the transition to a circular bioeconomy. Stora Enso has approximately 19,000 employees and our sales in 2025 were EUR 9.3 billion. Stora Enso’s shares are listed on Nasdaq Helsinki Oy (STEAV, STERV) and Nasdaq Stockholm AB (STE A, STE R). In addition, the shares are traded on OTC Markets (OTCQX) in the USA as ADRs and ordinary shares (SEOAY, SEOFF, SEOJF). storaenso.com/investors

STORA ENSO OYJ

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/stora-enso-oyj/r/stora-enso-interim-report-january-march-2026–focus-on-our-own-actions-drives-results,c4345733

The following files are available for download:

 

View original content:https://www.prnewswire.com/news-releases/stora-enso-interim-report-januarymarch-2026-focus-on-our-own-actions-drives-results-302765209.html

SOURCE Stora Enso Oyj